Back to Agendas
Breakthrough Medicines or Affordable Health Care: Do We Have to Choose?
Session Chair(s)
Kenneth I. Kaitin, PhD
Professor and Senior Fellow
Tufts Center for the Study of Drug Development, United States
A recent study by the Tufts Center for the Study of Drug Development reported that it cost $2.6 billion to bring a new medicine to market, more than double the cost of a decade ago. This high cost of development highlights the importance for drug sponsors to generate an adequate rate of return on their investment. However, as overall health care costs continue to rise, pharmaceutical companies are under increasing pressure to demonstrate the economic value of their products and justify prices. In this forum, panelists will explore the potentially competing demands for innovative breakthrough medicines and health care cost containment, and will examine regulatory initiatives and new business practices geared toward boosting innovation while lowering treatment costs.
Learning Objective : Describe the competing demands for innovative breakthrough medicines and health care cost containment; Discuss regulatory initiatives and new business practices geared toward boosting innovation while lowering treatment costs.
Speaker(s)
Panelist
Hans-Georg Eichler, MD, MSc
Austrian Association of Social Security Bodies, Austria
Consulting Physician
Panelist
Ellen Sigal, PhD
Friends of Cancer Research, United States
Chairperson and Founder
Panelist
Margaret A. Anderson, MA
FasterCures, A Center of the Milken Institute, United States
Executive Director
Panelist
Charles A. Stevens, JD, MBA
PAREXEL Consulting, United States
Vice President and General Manager
Panelist
David Vulcano, MBA, RAC
HCA Healthcare | Society Clinical Research Sites, United States
Honorary President (SCRS); VP, Clinical Research Compliance and Integrity (HCA
Have an account?